In recent years, there have been numerous significant advances in the field of Hodgkin lymphoma (HL) both from a scientific and a clinical perspective, and outcomes have continued to improve for patients with HL across all lines of therapy. Nonetheless, there remain many areas where there is the opportunity to minimize toxicity whilst improving efficacy, and the coming years will likely see further incorporation of novel therapeutics into earlier lines of therapy. Furthermore, advances in HL have not benefited all patients equally as delivery of adequate therapy remains a challenge in many groups, including elderly patients and patients from lower-income countries.
In this collection, we aim to collate manuscripts focused on novel research into the treatment of Hodgkin lymphoma. In particular, we welcome manuscripts on, but not limited to, the following research areas:
• Advances in disease biology contributing to novel treatment approaches for HL, in particular those targeting the tumor microenvironment (TME)
• Management of newly diagnosed HL in the pediatric population
• Frontline management of early stage HL in adults
• Frontline management of advanced stage HL with a focus on emerging data regarding the incorporation of checkpoint inhibitors in newly diagnosed disease
• Management of relapsed/refractory HL in patients who are transplant-eligible
• Considerations for autologous and allogeneic stem cell transplant in HL
• Considerations for the management of HL in elderly patients
• Management of HL in low- and low-middle-income countries
• Immuno- and cellular therapy (excluding PD-1 blockade) in HL
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
In recent years, there have been numerous significant advances in the field of Hodgkin lymphoma (HL) both from a scientific and a clinical perspective, and outcomes have continued to improve for patients with HL across all lines of therapy. Nonetheless, there remain many areas where there is the opportunity to minimize toxicity whilst improving efficacy, and the coming years will likely see further incorporation of novel therapeutics into earlier lines of therapy. Furthermore, advances in HL have not benefited all patients equally as delivery of adequate therapy remains a challenge in many groups, including elderly patients and patients from lower-income countries.
In this collection, we aim to collate manuscripts focused on novel research into the treatment of Hodgkin lymphoma. In particular, we welcome manuscripts on, but not limited to, the following research areas:
• Advances in disease biology contributing to novel treatment approaches for HL, in particular those targeting the tumor microenvironment (TME)
• Management of newly diagnosed HL in the pediatric population
• Frontline management of early stage HL in adults
• Frontline management of advanced stage HL with a focus on emerging data regarding the incorporation of checkpoint inhibitors in newly diagnosed disease
• Management of relapsed/refractory HL in patients who are transplant-eligible
• Considerations for autologous and allogeneic stem cell transplant in HL
• Considerations for the management of HL in elderly patients
• Management of HL in low- and low-middle-income countries
• Immuno- and cellular therapy (excluding PD-1 blockade) in HL
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
